Company / Return on Equity (ROE)
InMed Pharmaceuticals Inc. Return on Equity (ROE) History
FY2022-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Equity (ROE)
-83.4%
FY2025
5-year range
-204.9% / -65.7%
FY2022-FY2025
Trend
-26.8%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
InMed Pharmaceuticals Inc. reports negative total equity of -83.4% in FY2025. Negative equity can occur when accumulated losses exceed contributed capital, as reported in the balance sheet from the SEC filing.
Based on SEC 10-K filings.
-83.4% in FY2025 with a 3-year CAGR of +54.9%.
Improved from -204.9% to -83.4% over the past 2 years.
Return on Equity (ROE) over time
Growth rates
- 3-Year Change
- +54.9pp
- 5-Year Change
- -
- 10-Year Change
- -
Key checks
Key Insights
- In FY2025, return on equity (roe) decreased 26.8% year-over-year.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Equity (ROE)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -83.4% | -26.8% |
| FY2024 | -65.7% | +67.9% |
| FY2023 | -204.9% | -48.1% |
| FY2022 | -138.3% | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026